Home LiteratureArticle Details
PMID: 789084 Published · ppublish English Clinical Trial Comparative Study Journal Article

Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection.

European journal of clinical pharmacology ·Vol. 10 ·No. 5 ·1976-09-30 ·Pages 357-65

Roth S, Naber K, Scheer M, Gruenwaldt G, Lange H

Abstract

Serum concentration, biological half-life, distribution space and serum clearance of sisomicin, a new aminoglycoside antibiotic, have been studied in twenty-three patients in comparison with the pharmacokinetics of 125I-labelled iothalamate, a compound only filtered by the kidney. 10 patients had normal or borderline abnormal serum creatinine (less than 1,5 mg/100 ml), 8 had various degrees of renal insufficiency (serum creatinine 1.7-9.6 mg/100 ml) and 6 were being treated by intermittent haemodialysis. After intravenous injection of sisomicin 1 mg/kg body weight in patients with normal or borderline renal function its half-life was 3.5 h, very similar to that of iothalamate, 3.2 h. The mean distribution space was 20.1% per cent of body weight; iothalamate, 23.7%. In patients with renal insufficiency there was a positive correlation between serum creatinine level and the half-life of sisomicin, and an even stronger correlation between the clearances of iothalamate and sisomicin. In patients dependent on haemodialysis, the mean serum half-life between dialysis was 40 h, compared to approximately 100 hours for iothalamate, which implies additional extrarenal clearance or tubular secretion of sisomicin. The results of pharmacokinetic studies indicated that a regime of sisomicin 1 mg/kg every 8 to 12 hours in patients with normal renal function would result in serum and urine levels sufficiently high to treat most urinary tract infections. In patients with impaired renal function the dosage interval should be increased according to the serum creatinine level, and in patients dependent on haemodialysis one standard dose at the end of each dialysis period should suffice. 9 patients with a chronic urinary tract infection severely complicated by an underlying disease were treated according to this dosage regimen with a satisfactory bacteriological and clinical result. No adverse reactions or signs of accumulation were observed.

MeSH Terms
Adult Aged Anti-Bacterial Agents/therapeutic use Clinical Trials as Topic Drug Evaluation Drug Resistance, Microbial Female Glomerular Filtration Rate Half-Life Humans Iothalamic Acid/metabolism Kidney Diseases/drug therapy,metabolism Male Middle Aged Renal Dialysis Sisomicin/metabolism,therapeutic use Urinary Tract Infections/drug therapy
Chemicals
Anti-Bacterial Agents Iothalamic Acid Sisomicin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Roth S
Naber K
Scheer M
Gruenwaldt G
Lange H
References (16)
16 references, click to expand
  1. Sisomicin: evaluation in vitro and comparison with gentamicin and tobramycin.
    Antimicrob Agents Chemother. 1973 Jan;3(1):24-8 PMID: 4790572
  2. Pharmacokinetics of a new cephalosporin, cephacetrile, in patients with normal and impaired renal function.
    Infection. 1973;1(3):157-62 PMID: 4597098
  3. [Binding of sisomicin and gentamicin to serum proteins (author's transl)].
    Arzneimittelforschung. 1976;26(8):1517-21 PMID: 1036948
  4. In vitro bactericidal effectiveness of four aminoglycoside antibiotics.
    Antimicrob Agents Chemother. 1973 Jan;3(1):87-94 PMID: 4790579
  5. The measurement of glomerular filtration rate in man with sodium iothalamate 131-I (Conray).
    J Nucl Med. 1966 Jan;7(1):60-8 PMID: 5907195
  6. Pharmacokinetics of gentamicin: distribution and plasma and renal clearance.
    J Infect Dis. 1971 Dec;124 Suppl:S70-6 PMID: 5126251
  7. Antibiotic 6640. 3. Biological studies with antibiotic 6640, a new broad-spectrum aminoglycoside antibiotic.
    J Antibiot (Tokyo). 1970 Nov;23(11):559-65 PMID: 4992170
  8. Renal hemodynamics and limitations of creatinine clearance in determining filtration rate in glomerular disease.
    Scand J Urol Nephrol. 1971;5(2):154-61 PMID: 4937335
  9. Antipseudomonal drugs: comparative study of gentamicin, sisomicin and tobramycin in vitro and in human volunteers.
    Eur J Cancer. 1973 Sep;9(9):641-8 PMID: 4214702
  10. Serum protein binding of the aminoglycoside antibiotics.
    Antimicrob Agents Chemother. 1972 Sep;2(3):214-6 PMID: 4790560
  11. Antibiotic 6640, a new Micromonospora-produced aminoglycoside antibiotic.
    J Antibiot (Tokyo). 1970 Nov;23(11):551-4 PMID: 5487129
  12. [Pharmacological and therapeutic properties of gentamicin. Experimental studies on the effect level, excretion, stability and therapeutic indications].
    Arzneimittelforschung. 1968 Sep;18(9):1119-23 PMID: 4974678
  13. PHARMACOLOGY OF GENTAMICIN, A NEW BROAD-SPECTRUM ANTIBIOTIC.
    Antimicrob Agents Chemother (Bethesda). 1963;161:138-47 PMID: 14274880
  14. The measurement of glomerular filtration rate and effective renal plasma flow in man by iothalamate 125-I and iodopyracet 131-I.
    Circulation. 1967 Sep;36(3):441-8 PMID: 6033171
  15. In vitro comparison of four aminoglycoside antibiotics: sisomicin, gentamicin, tobramycin, and BB-K8.
    Antimicrob Agents Chemother. 1974 Jun;5(6):667-9 PMID: 15825423
  16. Pharmacokinetics of the aminoglycoside antibiotic tobramycin in humans.
    Antimicrob Agents Chemother. 1973 Apr;3(4):469-73 PMID: 4208290
Article Info
Journal
European journal of clinical pharmacology
Abbr.
Eur J Clin Pharmacol
ISSN
0031-6970
Published
1976-09-30
Pages
357-65
Language
English
Region
Germany
NLM ID
1256165
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com